These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 19856059

  • 1. Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
    Hasegawa Y, Mita K, Matsubara A, Ohdan H.
    Int J Clin Oncol; 2009 Oct; 14(5):465-7. PubMed ID: 19856059
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ.
    J Clin Oncol; 2007 Aug 01; 25(22):3288-95. PubMed ID: 17664476
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
    Negrier S, Jäger E, Porta C, McDermott D, Moore M, Bellmunt J, Anderson S, Cihon F, Lewis J, Escudier B, Bukowski R.
    Med Oncol; 2010 Sep 01; 27(3):899-906. PubMed ID: 19757215
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C.
    Clin Cancer Res; 2007 Mar 15; 13(6):1801-9. PubMed ID: 17363536
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
    Sciarra A, Autran Gomez AM, Gentilucci A, Parente U, Salciccia S, Gentile V, Di Silverio F.
    Eur Urol; 2007 Aug 15; 52(2):597-9. PubMed ID: 17420088
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases].
    Arima S, Shiroki R, Mori S, Maruyama T, Sasaki H, Kusaka M, Miyakawa S, Hayakawa K, Hoshinaga K.
    Nihon Hinyokika Gakkai Zasshi; 2008 Jul 15; 99(5):660-5. PubMed ID: 18697474
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V.
    Eur Urol; 2009 Jun 15; 55(6):1430-8. PubMed ID: 18950936
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
    Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, Abrahamova J.
    Ann Oncol; 2012 Feb 15; 23(2):395-401. PubMed ID: 21536664
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.